It feels as though novel potential therapies for Parkinson’s are being proposed with an ever increasing frequency. And just when I think there must be few other ways of attacking the condition, a new method is proposed. Recently a biotech firm called Clene Nanomedicine presented data on one such new approach.
The experimental treatment is called CNM-Au8 and it involves gold. Yes, that gold.
And the treatment is already being tested in a clinical trial for Parkinson’s.
In today’s post, we will look at what CNM-Au8 is and what it does, we’ll discuss what data has been presented, and then we’ll outline what the clinical trial involves.
Although I did not attend the Society for Neuroscience 2019 annual meeting in Chicago in October, I have still had a look at some of the 816 abstracts which had the keyword “Parkinson’s” attached to them (my Saturday night entertainment – sad I know!).
Those abstracts can be found online (Click here to search those abstracts).
One in particular abstract caught my attention:
This poster was presented by research scientists from a biotech company that I had never heard of called Clene Nanomedicine:
And the data presented focused on a novel therapy that I had never heard of which is now being targetted at Parkinson’s.
The new treatment is called CNM-Au8.
What is CNM-Au8?